April 16 (Reuters) - Abbott Laboratories ABT.N beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices.
The company also maintained its full-year profit forecast of $5.05 to $5.25 per share in the face of an escalating global trade war.
Abbott is likely to face a hit from the heavy duties imposed on other countries given its broad manufacturing footprint across the world, according to analysts.
On an adjusted basis, the company's quarterly profit of $1.09 per share beat analysts' average expectations of $1.07 per share, according to estimates compiled by LSEG.
(Reporting by Christy Santhosh and Puyaan Singh in Bengaluru; Editing by Leroy Leo)
((Christy.Santhosh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.